Biomea Fusion

Dilution score: 18/100 (LOW), 24.0 months cash

Short interest: 21.35% of float, squeeze risk: HIGH

103 PubMed publications found for Biomea Fusion

Assessing the efficacy, safety and utility of fully closed-loop insulin delivery compared to standard insulin therapy with a continuous glucose monitor in adults with type 2 diabetes (COYOTE study): a randomised parallel study protocol.

HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results.

CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuum.

Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial.

Continuous glucose monitoring versus self-monitoring of blood glucose in individuals with type 2 diabetes: a randomised, multicentre, open-label, superiority trial.

Dilution score: 49/100 (MEDIUM), 16.3 months cash

102 PubMed publications found for Biomea Fusion

Short interest: 21.29% of float, squeeze risk: HIGH

SW convergence: 50/100 (Neutral), 0 bullish / 0 bearish signals

100 PubMed publications found for Biomea Fusion

Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial.

Assessment of early return to drinking in surviving patients with alcohol-associated hepatitis.

99 PubMed publications found for Biomea Fusion

Dilution score: 49/100 (MEDIUM), 15.9 months cash

Short interest: 20.9% of float, squeeze risk: HIGH

98 PubMed publications found for Biomea Fusion

GLP-1 receptor agonists or SGLT2-inhibitors? Evaluation of a personalized treatment algorithm for individuals with type 2 diabetes: a registry-based cohort study.

97 PubMed publications found for Biomea Fusion

Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.

Dilution score: 47/100 (MEDIUM), 15.9 months cash

96 PubMed publications found for Biomea Fusion

95 PubMed publications found for Biomea Fusion

Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trial.

<article class="bts-verified-summary" data-ticker="BMEA">
<p>Biomea Fusion (BMEA) is the lead sponsor of 4 active clinical trials listed on ClinicalTrials.gov<sup><a href="#fn-3">[3]</a></sup>, including 2 Phase 2<sup><a href="#fn-1">[1]</a></sup>, 2 Phase 1<sup><a href="#fn-2">[2]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">ClinicalTrials.gov (2026-04-11) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Biomea+Fusion%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-2">ClinicalTrials.gov (2026-04-11) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Biomea+Fusion%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-3">ClinicalTrials.gov (2026-04-11) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Biomea+Fusion%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

ClinicalTrials.gov

Biomea Fusion (BMEA) — BioTechSigns Verified Summary

Biomea Fusion (BMEA) is the lead sponsor of 4 active clinical trials listed on ClinicalTrials.gov[3], including 2 Phase 2[1], 2 Phase 1[2].

Sources:
[1] ClinicalTrials.gov. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Biomea+Fusion%22&aggFilters=status%3Arec%2Cact
[2] ClinicalTrials.gov. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Biomea+Fusion%22&aggFilters=status%3Arec%2Cact
[3] ClinicalTrials.gov. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Biomea+Fusion%22&aggFilters=status%3Arec%2Cact

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia.

A Phase 1 Study of BMF-500 in Adults With Acute Leukemia

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMF-650 in Otherwise Healthy Overweight or Obese Participants.

Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants

This is a Phase 2, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of icovamenib in participants with Type 2 Diabetes who are not achieving glycemic targets despite antihyperglycemic medications.

Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets

This is a phase 2 randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of icovamenib in participants with Type 2 Diabetes (T2D) not achieving glycemic targets despite Ozempic-based therapy.